JP5096466B2 - Ｎ末端ポリシアリル化 - Google Patents

Ｎ末端ポリシアリル化 Download PDF

Info

Publication number
JP5096466B2
JP5096466B2 JP2009521337A JP2009521337A JP5096466B2 JP 5096466 B2 JP5096466 B2 JP 5096466B2 JP 2009521337 A JP2009521337 A JP 2009521337A JP 2009521337 A JP2009521337 A JP 2009521337A JP 5096466 B2 JP5096466 B2 JP 5096466B2
Authority
JP
Japan
Prior art keywords
insulin
polysaccharide
protein
chain
terminus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009521337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544678A (ja
Inventor
サンジャイ ジェイン
ロンシェン ザン
Original Assignee
リポクセン テクノロジーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リポクセン テクノロジーズ リミテッド filed Critical リポクセン テクノロジーズ リミテッド
Publication of JP2009544678A publication Critical patent/JP2009544678A/ja
Application granted granted Critical
Publication of JP5096466B2 publication Critical patent/JP5096466B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
JP2009521337A 2006-07-25 2007-07-25 Ｎ末端ポリシアリル化 Expired - Fee Related JP5096466B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06117830 2006-07-25
EP06117830.7 2006-07-25
PCT/GB2007/002821 WO2008012528A1 (en) 2006-07-25 2007-07-25 N-terminal polysialylation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012205475A Division JP5586669B2 (ja) 2006-07-25 2012-09-19 Ｎ末端ポリシアリル化

Publications (2)

Publication Number Publication Date
JP2009544678A JP2009544678A (ja) 2009-12-17
JP5096466B2 true JP5096466B2 (ja) 2012-12-12

Family

ID=37397314

Family Applications (14)

Application Number Title Priority Date Filing Date
JP2009521337A Expired - Fee Related JP5096466B2 (ja) 2006-07-25 2007-07-25 Ｎ末端ポリシアリル化
JP2009521336A Expired - Fee Related JP5419689B2 (ja) 2006-07-25 2007-07-25 顆粒球コロニー刺激因子の誘導体化
JP2009521342A Pending JP2009544680A (ja) 2006-07-25 2007-07-25 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2009521343A Pending JP2009544681A (ja) 2006-07-25 2007-07-25 エリスロポエチンの多糖誘導体
JP2012205475A Expired - Fee Related JP5586669B2 (ja) 2006-07-25 2012-09-19 Ｎ末端ポリシアリル化
JP2012287324A Active JP5542195B2 (ja) 2006-07-25 2012-12-28 エリスロポエチンの多糖誘導体
JP2013022825A Expired - Fee Related JP5420091B2 (ja) 2006-07-25 2013-02-08 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2013160269A Active JP5941440B2 (ja) 2006-07-25 2013-08-01 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2014025061A Active JP6165079B2 (ja) 2006-07-25 2014-02-13 エリスロポエチンの多糖誘導体
JP2014154037A Active JP5912152B2 (ja) 2006-07-25 2014-07-29 Ｎ末端ポリシアリル化
JP2015075148A Expired - Fee Related JP6055506B2 (ja) 2006-07-25 2015-04-01 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2016020557A Expired - Fee Related JP6243456B2 (ja) 2006-07-25 2016-02-05 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2016149090A Expired - Fee Related JP6203342B2 (ja) 2006-07-25 2016-07-29 エリスロポエチンの多糖誘導体
JP2017157728A Expired - Fee Related JP6581157B2 (ja) 2006-07-25 2017-08-18 エリスロポエチンの多糖誘導体

Family Applications After (13)

Application Number Title Priority Date Filing Date
JP2009521336A Expired - Fee Related JP5419689B2 (ja) 2006-07-25 2007-07-25 顆粒球コロニー刺激因子の誘導体化
JP2009521342A Pending JP2009544680A (ja) 2006-07-25 2007-07-25 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2009521343A Pending JP2009544681A (ja) 2006-07-25 2007-07-25 エリスロポエチンの多糖誘導体
JP2012205475A Expired - Fee Related JP5586669B2 (ja) 2006-07-25 2012-09-19 Ｎ末端ポリシアリル化
JP2012287324A Active JP5542195B2 (ja) 2006-07-25 2012-12-28 エリスロポエチンの多糖誘導体
JP2013022825A Expired - Fee Related JP5420091B2 (ja) 2006-07-25 2013-02-08 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2013160269A Active JP5941440B2 (ja) 2006-07-25 2013-08-01 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2014025061A Active JP6165079B2 (ja) 2006-07-25 2014-02-13 エリスロポエチンの多糖誘導体
JP2014154037A Active JP5912152B2 (ja) 2006-07-25 2014-07-29 Ｎ末端ポリシアリル化
JP2015075148A Expired - Fee Related JP6055506B2 (ja) 2006-07-25 2015-04-01 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2016020557A Expired - Fee Related JP6243456B2 (ja) 2006-07-25 2016-02-05 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2016149090A Expired - Fee Related JP6203342B2 (ja) 2006-07-25 2016-07-29 エリスロポエチンの多糖誘導体
JP2017157728A Expired - Fee Related JP6581157B2 (ja) 2006-07-25 2017-08-18 エリスロポエチンの多糖誘導体

Country Status (10)

Country Link
US (22) US10300144B2 (enExample)
EP (6) EP3299033A1 (enExample)
JP (14) JP5096466B2 (enExample)
KR (1) KR101400105B1 (enExample)
CN (2) CN101511391B (enExample)
AT (1) ATE467642T1 (enExample)
DE (1) DE602007006492D1 (enExample)
ES (5) ES2581902T3 (enExample)
RU (1) RU2432175C2 (enExample)
WO (4) WO2008012528A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013049675A (ja) * 2006-07-25 2013-03-14 Lipoxen Technologies Ltd Ｎ末端ポリシアリル化

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2294535T3 (es) 2003-08-12 2008-04-01 Lipoxen Technologies Limited Derivados del acido polisialico.
KR101113726B1 (ko) 2003-08-12 2012-02-27 리폭센 테크놀로지즈 리미티드 단백질 유도 및 컨쥬게이션용 시알산 유도체
CN105838699A (zh) 2006-12-15 2016-08-10 巴克斯艾尔塔公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
PL2115010T3 (pl) 2007-02-28 2012-07-31 Lipoxen Tech Limited Zmniejszanie zawartości endotoksyny w kwasach polisialowych
BRPI0815324A2 (pt) 2007-08-20 2015-07-14 Protalix Ltd "conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos"
RU2391354C1 (ru) * 2008-10-15 2010-06-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН, Российская Федерация, от имени которой выступает Федеральное агентство по науке и инновациям Комплекс биологически активного рекомбинантного белка с полисиаловой кислотой
WO2010089756A2 (en) * 2008-10-20 2010-08-12 Usv Limited An improved process for pegylation of proteins
WO2010051335A1 (en) * 2008-10-31 2010-05-06 Amgen Inc. Materials and methods relating to stem cell mobilization by multi-pegylated granulocyte colony stimulating factor
AU2010208305A1 (en) 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
RU2011135730A (ru) 2009-01-28 2013-03-10 Смартселлз, Инк. Кристаллические инсулин-коньюгаты
KR101635689B1 (ko) 2009-01-28 2016-07-01 스마트쎌스, 인크. 제어 약물 전달을 위한 접합체 기재 시스템
US8846103B2 (en) 2009-01-28 2014-09-30 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
US8569231B2 (en) 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
US8623345B2 (en) 2009-03-20 2014-01-07 Smartcells Terminally-functionalized conjugates and uses thereof
EP2459226B1 (en) * 2009-07-27 2016-06-29 Lipoxen Technologies Limited Glycopolysialylation of proteins other than blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP2459224B1 (en) 2009-07-27 2016-06-01 Baxalta GmbH Blood coagulation protein conjugates
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
PL2459224T3 (pl) * 2009-07-27 2017-08-31 Baxalta GmbH Koniugaty białka związanego z krzepnięciem krwi
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
CN101787117B (zh) * 2010-02-08 2012-05-23 江南大学 聚乙二醇-聚唾液酸嵌段共聚物的制备方法及应用
KR20130115086A (ko) * 2010-05-17 2013-10-21 세빅스 인코포레이티드 페길화된 c-펩티드
US20120034631A1 (en) * 2010-06-11 2012-02-09 Wojciak Jonathan Michael Anti-lysophospholipid antibody design using antibody structures
WO2012015692A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
WO2012015691A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
AU2011282977A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
ES2774190T3 (es) 2011-01-20 2020-07-17 Protalix Ltd Composiciones de alfa-galactosidasa
EP2780030A4 (en) 2011-11-17 2015-11-18 Cebix Ab PEGYLATED C-PEPTIDE
TW201605470A (zh) 2013-10-04 2016-02-16 默沙東藥廠 葡萄糖反應性胰島素結合物
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
JP2019218265A (ja) * 2016-09-14 2019-12-26 生化学工業株式会社 ペプチドの血中滞留性を増強させる方法
WO2018197545A1 (en) * 2017-04-25 2018-11-01 Lipoxen Technologies Limited Methods of treating multiple myeloma cancers expressing high levels of epo-receptor using psa-epo
WO2018197547A1 (en) 2017-04-25 2018-11-01 Lipoxen Technologies Limited Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i
WO2020099513A1 (en) * 2018-11-13 2020-05-22 Lipoxen Technologies Limited Glycopolysialylation of blinatumomab
WO2020163269A1 (en) * 2019-02-04 2020-08-13 Xenetic Biosciences, Inc. Methods of using glycopolysialylated therapeutic proteins
PE20220098A1 (es) 2019-07-08 2022-01-24 Gi Innovation Inc Dimero polipeptido con alto contenido en acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige, y composicion farmaceutica que comprende el mismo
CN116249552A (zh) * 2020-08-11 2023-06-09 隆延生物科技（上海）有限公司 一种液体制剂及其应用
CN114966021B (zh) * 2022-05-19 2025-03-04 山东博科生物产业有限公司 一种稳定的脂蛋白相关磷脂酶a2测定试剂盒

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2930542A1 (de) 1979-07-27 1981-02-12 Hoechst Ag Neue insulinderivate und verfahren zu ihrer herstellung
US5308617A (en) * 1988-08-10 1994-05-03 Halzyme Ltd. Protein heparin conjugates
US7217689B1 (en) * 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
KR100221066B1 (ko) 1989-10-13 1999-10-01 스튜어트 엘.왓트 에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물
GB9112212D0 (en) 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
US5846951A (en) * 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
EP0550108B1 (en) 1991-12-30 1998-03-18 Akzo Nobel N.V. Sustained release thyroactive composition
JP2747967B2 (ja) * 1993-07-23 1998-05-06 雪印乳業株式会社 シアル酸粉末
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DK1003525T3 (da) * 1997-08-05 2003-03-24 Bioniche Life Sciences Inc Præparat og fremgangsmåde til regulering af celleproliferation og celledød
AU2794199A (en) 1998-02-26 1999-09-15 Robertas Bunevicius Thyroid hormone replacement using sustained release triiodothyronine
RU2141531C1 (ru) 1999-05-26 1999-11-20 Российское акционерное общество открытого типа "Биопрепарат" Способ получения рекомбинантного инсулина человека
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
WO2001087922A2 (en) 2000-05-16 2001-11-22 Lipoxen Technologies Limited Derivatisation of proteins in aqueous solution
ES2257412T3 (es) 2000-05-18 2006-08-01 Therics, Inc. Encapsulacion de un nucleo toxico en una region no toxica en una forma de dosificacion oral.
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
ATE421535T1 (de) 2000-10-16 2009-02-15 Chugai Pharmaceutical Co Ltd Peg-modifiziertes erythropoietin
AU2002233230B2 (en) 2000-12-20 2007-02-01 F. Hoffmann-La Roche Ag Erythropoietin conjugates
KR100401296B1 (ko) 2000-12-27 2003-10-11 드림바이오젠 주식회사 수식물질에 의해 수식된 단백질 변이체 및 이것의 제조방법
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
ES2561985T3 (es) * 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
WO2003055526A2 (en) 2001-12-21 2003-07-10 Maxygen Aps Erythropoietin conjugates
ITPD20010302A1 (it) 2001-12-28 2003-06-28 Bbs Riva Spa Dispositivo idraulico per pompare e / p intercettare metallo allo stato fuso
US6763226B1 (en) 2002-07-31 2004-07-13 Computer Science Central, Inc. Multifunctional world wide walkie talkie, a tri-frequency cellular-satellite wireless instant messenger computer and network for establishing global wireless volp quality of service (qos) communications, unified messaging, and video conferencing via the internet
EP1400533A1 (en) * 2002-09-11 2004-03-24 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
EP1681303B1 (en) 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
AU2003255406B2 (en) * 2002-09-11 2009-09-10 Fresenius Kabi Deutschland Gmbh Hydroxyalkyl starch derivatives
CN101514223B (zh) 2003-04-11 2017-03-01 安特里阿比奥有限公司 位点特异性蛋白质偶联物的制备方法
WO2004101619A1 (ja) * 2003-05-15 2004-11-25 Shionogi Co., Ltd. 機能的糖ペプチドの合理的設計および合成
US7074755B2 (en) 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
US7550593B2 (en) 2003-07-03 2009-06-23 Cipla Limited Process for the preparation of finasteride Form I
EP1651547B1 (en) 2003-08-05 2006-11-22 Dematic Corp. Motorized roller transverse drive
BRPI0413309B8 (pt) 2003-08-06 2021-05-25 The Government Of The Us Secretary Department Of Health And Human Services método para a preparação de uma vacina conjugada de polissacarídeo-proteína
PL1660134T3 (pl) * 2003-08-08 2011-05-31 Fresenius Kabi Deutschland Gmbh Koniugaty hydroksyalkiloskrobi i G-CSF
KR101113726B1 (ko) * 2003-08-12 2012-02-27 리폭센 테크놀로지즈 리미티드 단백질 유도 및 컨쥬게이션용 시알산 유도체
ES2294535T3 (es) * 2003-08-12 2008-04-01 Lipoxen Technologies Limited Derivados del acido polisialico.
US20070254834A1 (en) * 2003-11-24 2007-11-01 Defrees Shawn Glycopegylated Erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
CN1897812B (zh) 2003-12-03 2011-08-17 生物种属学股份公司 糖聚乙二醇化的粒细胞集落刺激因子
DE202005021885U1 (de) * 2004-03-11 2011-03-03 Fresenius Kabi Deutschland Gmbh Hydroxyalkylstärke-Protein-Konjugate, durch reduktive Aminierung hergestellt
FR2868071B1 (fr) * 2004-03-26 2006-06-09 Biomerieux Sa Reactifs de marquage, procedes de synthese de tels reactifs et procedes de detection de molecules biologiques
DE102004030392A1 (de) 2004-06-23 2006-01-19 Endress + Hauser Flowtec Ag, Reinach Meßwandler vom Vibrationstyp
WO2006014148A2 (fr) 2004-08-04 2006-02-09 Sergey Alexandrovich Orlov Procede permettant d'organiser un processus de jeu a action intermittente
GB2416993A (en) 2004-08-11 2006-02-15 Dinesh Verma Opthalmic prosthesis
US7875708B2 (en) * 2004-08-12 2011-01-25 Lipoxen Technologies Limited Sialic acid derivatives
JP5026266B2 (ja) 2004-08-12 2012-09-12 リポクセン テクノロジーズ リミテッド 分別
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
CN101160326B (zh) 2005-02-23 2013-04-10 利普生技术有限公司 用于蛋白质衍生和缀合的活化的唾液酸衍生物
JP3989936B2 (ja) * 2005-04-07 2007-10-10 進 須永 抗腫瘍剤及び新規ｄｎアーゼ
WO2007047997A2 (en) 2005-10-19 2007-04-26 Smartcells, Inc. Methods for reducing the mitogenicity of lectin compositions
EP3299033A1 (en) * 2006-07-25 2018-03-28 Lipoxen Technologies Limited N-terminal polysialylation
WO2011007865A1 (ja) 2009-07-16 2011-01-20 花王株式会社 食後血中インスリン濃度上昇抑制剤
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013049675A (ja) * 2006-07-25 2013-03-14 Lipoxen Technologies Ltd Ｎ末端ポリシアリル化

Also Published As

Publication number Publication date
US20170080054A1 (en) 2017-03-23
EP2043616A1 (en) 2009-04-08
JP2018039791A (ja) 2018-03-15
WO2008012542A2 (en) 2008-01-31
US20100022443A1 (en) 2010-01-28
WO2008012540A9 (en) 2009-03-12
EP2041167A1 (en) 2009-04-01
US20160129124A1 (en) 2016-05-12
EP2043693B1 (en) 2016-04-27
JP2015007062A (ja) 2015-01-15
CN103169984A (zh) 2013-06-26
JP2013049675A (ja) 2013-03-14
US20160129123A1 (en) 2016-05-12
JP5542195B2 (ja) 2014-07-09
US20180289823A1 (en) 2018-10-11
WO2008012525A1 (en) 2008-01-31
JP6581157B2 (ja) 2019-09-25
US9040478B2 (en) 2015-05-26
US20140161765A1 (en) 2014-06-12
US20190216938A1 (en) 2019-07-18
US8394921B2 (en) 2013-03-12
US9492557B2 (en) 2016-11-15
US20140309407A1 (en) 2014-10-16
EP2043692B1 (en) 2016-05-18
US20130116176A1 (en) 2013-05-09
US9266936B2 (en) 2016-02-23
KR101400105B1 (ko) 2014-06-19
US20100016217A1 (en) 2010-01-21
US9234020B2 (en) 2016-01-12
US9549990B2 (en) 2017-01-24
US20140134147A1 (en) 2014-05-15
WO2008012525A8 (en) 2010-04-29
JP5912152B2 (ja) 2016-04-27
JP2015145400A (ja) 2015-08-13
JP5420091B2 (ja) 2014-02-19
US8933026B2 (en) 2015-01-13
EP2043616B1 (en) 2016-01-27
RU2432175C2 (ru) 2011-10-27
US20100056427A1 (en) 2010-03-04
JP2017018107A (ja) 2017-01-26
CN101511391A (zh) 2009-08-19
WO2008012528A1 (en) 2008-01-31
ATE467642T1 (de) 2010-05-15
US8299026B2 (en) 2012-10-30
JP2009544680A (ja) 2009-12-17
EP3299033A1 (en) 2018-03-28
KR20090057370A (ko) 2009-06-05
US20150147307A1 (en) 2015-05-28
US8981050B2 (en) 2015-03-17
JP2013100309A (ja) 2013-05-23
US20170119893A1 (en) 2017-05-04
JP2009544678A (ja) 2009-12-17
WO2008012542A8 (en) 2009-07-16
CN101511391B (zh) 2013-03-13
JP2014114315A (ja) 2014-06-26
EP2630972A3 (en) 2013-10-16
JP2009544681A (ja) 2009-12-17
JP2013121982A (ja) 2013-06-20
US20140315802A1 (en) 2014-10-23
US20220133898A1 (en) 2022-05-05
ES2647528T3 (es) 2017-12-22
EP2043693A1 (en) 2009-04-08
CN103169984B (zh) 2016-08-03
US20100022441A1 (en) 2010-01-28
ES2569066T3 (es) 2016-05-06
JP2013241446A (ja) 2013-12-05
EP2043692A2 (en) 2009-04-08
US8946406B2 (en) 2015-02-03
JP5419689B2 (ja) 2014-02-19
JP2016128493A (ja) 2016-07-14
US9579393B2 (en) 2017-02-28
JP6055506B2 (ja) 2016-12-27
JP5941440B2 (ja) 2016-06-29
US9474805B2 (en) 2016-10-25
US8299015B2 (en) 2012-10-30
US20170058273A1 (en) 2017-03-02
ES2344670T3 (es) 2010-09-02
US20160095930A1 (en) 2016-04-07
EP2630972A2 (en) 2013-08-28
JP6165079B2 (ja) 2017-07-19
JP2009544677A (ja) 2009-12-17
WO2008012540A1 (en) 2008-01-31
US9789163B2 (en) 2017-10-17
US10300144B2 (en) 2019-05-28
US20150158924A1 (en) 2015-06-11
WO2008012542A3 (en) 2008-05-15
ES2581983T3 (es) 2016-09-08
DE602007006492D1 (de) 2010-06-24
US9492556B2 (en) 2016-11-15
JP6243456B2 (ja) 2017-12-06
US20140309166A1 (en) 2014-10-16
US20150252090A1 (en) 2015-09-10
RU2009105696A (ru) 2010-08-27
US8796207B2 (en) 2014-08-05
ES2581902T3 (es) 2016-09-08
JP6203342B2 (ja) 2017-09-27
JP5586669B2 (ja) 2014-09-10
EP2041167B1 (en) 2010-05-12
EP2630972B1 (en) 2017-08-30

Similar Documents

Publication Publication Date Title
JP5096466B2 (ja) Ｎ末端ポリシアリル化
US5359030A (en) Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
CN104592382A (zh) 一种peg-长链脂肪烷定点修饰的人生长激素及其制备方法

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120821

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120920

R150 Certificate of patent or registration of utility model

Ref document number: 5096466

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150928

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees